To identify the crucial regulator of m6A modification in the progression of HR+HER2− BC, we screened the expression profiles of m6A writers (METTL3, METTL14 and WTAP) and m6A erasers (FTO and ALKBH5) in the GSE87455 platform. Here, ALKBH5 is linked to breast cancer.